反应详情

Prepared according to procedure Y by stirring 4-chloro-5-fluoro-3-methyl-2-(pyridin-2-yl)quinoline (29.7 mg, 0.11 mmol), 6′-morpholino-1′,2,2′,3,5,6-hexahydrospiro[pyran-4,3′-pyrrolo[3,2-b]pyridine] (30 mg, 0.11 mmol), XPhos precatalyst (7 mg, 0.01 mmol) and sodium tert butoxide (20.9 mg, 0.22 mmol) in toluene (3 mL) at 90° C. for 2 h. Purification by reverse phase HPLC (10 to 60% acetonitrile in water) gave 1′-(5-fluoro-3-methyl-2-(2-pyridinyl)-4-quinolinyl)-6′-(4-morpholinyl)-1′,2,2′,3,5,6-hexahydrospiro[pyran-4,3′-pyrrolo[3,2-b]pyridine]. 1H NMR (500 MHz, chloroform-d) δ ppm 8.65-8.84 (1H, m), 8.02-8.07 (1H, m), 7.86-7.96 (2H, m), 7.64 (1H, td, J=8.1, 5.4 Hz), 7.56 (1H, d, J=2.2 Hz), 7.42 (1H, ddd, J=6.8, 4.9, 2.0 Hz), 7.14-7.21 (1H, m), 5.77 (1H, d, J=2.2 Hz), 4.08-4.18 (2H, m), 3.91-4.02 (2H, m), 3.70-3.80 (4H, m), 3.51-3.63 (2H, m), 2.95-3.05 (4H, m), 2.42-2.45 (3H, s), 2.35-2.40 (1H, m), 2.28 (1H, ddd, J=13.7, 11.5, 4.4 Hz), 1.85 (1H, ddd, J=13.6, 1.5, 1.3 Hz), 1.70-1.76 (1H, m). Mass Spectrum (ESI) m/e=512.0 (M+1).

1. customPrepared
2. customPurification by reverse phase HPLC (10 to 60% acetonitrile in water)